Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 25, 2017
Pharmacy Choice - Pharmaceutical News - Sanofi's Xyzal Allergy 24HR Approved for Over-the-Counter Use in the United States - February 25, 2017

Pharmacy News Article

 2/13/17 - Sanofi's Xyzal Allergy 24HR Approved for Over-the-Counter Use in the United States

By a News Reporter-Staff News Editor at Pharma Business Week HYPERLINK "http://www.sanofi.com/" \nSanofi announced that the U.S. Food and Drug Administration (FDA) approved Xyzal Allergy 24HR as an over-the-counter (OTC) treatment for the relief of symptoms associated with seasonal and year-round allergies. Specifically, two formulations of Xyzal are now approved for OTC use - 5 mg tablets for ages 6 years and older, as well as 0.5 mg/mL oral solution for ages 2 years and older. Xyzal is an oral antihistamine with a proven 24-hour effect.

"The FDA approval of Xyzal builds on our heritage of successful Rx-to-OTC switches, and adds another trusted option to our existing portfolio of OTC allergy medications," said Robert Long, Head of North America Consumer Healthcare, Sanofi. "We look forward to making it available to allergy sufferers across the country, as the latest product in our growing consumer healthcare business."

As many as 60 million Americans suffer from allergic rhinitis, which is also commonly known as hay fever.1 Antihistamines are the most widely used medications to relieve hay fever symptoms.2 Xyzal is an antihistamine that contains the active ingredient levocetirizine dihydrochloride, which has a well-established safety and efficacy profile. It offers 24-hour relief from runny nose, sneezing, itchy watery eyes and itching of the nose or throat, all in a single daily dose (see also Pharmaceutical Companies).

Sanofi Consumer Healthcare's existing allergy portfolio includes Allegra Allergy, which was approved for OTC use in 2011 and Nasacort Allergy 24HR, which was approved for OTC use in 2013. The company anticipates that Xyzal will be made available in Spring 2017.

Keywords for this news article include: Pharmaceutical Companies, Sanofi, Allergies, Immune System Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC



(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Feb 27: Acne Vulgaris: Comprehensive Pharmaceutical Care
Feb 28: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Mar 02: Type II Diabetes: Case Studies and Management Options
Mar 03: Anticoagulants: The Rapidly Changing Landscape
Mar 06: Vitamins, Minerals, and Electrolytes in Older Adults
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415